WuXi AppTec and Juno Therapeutics' joint cancer immunotherapy venture has listed on the Hong Kong Stock Exchange.

JW Therapeutics, the China-based cancer drug developer founded by corporates Juno Therapeutics and WuXi AppTec, has floated in an initial public offering that raised approximately HK$2.33bn ($300m) according to BioWorld.

The company issued 97.7 million shares priced at HK$23.80 each on the Hong Kong Stock Exchange and the offering was 450-times oversubscribed, BioWorld reported. Goldman Sachs and UBS are joint sponsors for the IPO.

Founded in 2016, JW is working on immuno-oncology therapies focused on chimeric antigen receptor (CAR) T-cells,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn